Beneficial effects of angiotensin II AT1 blocker on cardiovascular adverse remodeling due to nitric oxide synthesis blockade;Efectos beneficiosos del bloqueador AT1 de la angiotensina II en la remodelación cardiovascular adversa causada por el bloqueo de la síntesis de óxido Nítrico

International Journal of Morphology

Volumn 24, Issue 3, 2006, Pages 309-318

  Fernandes Santos, Caroline ^a   Mendonça, Leonardo De Souza ^a   Mandarim de Lacerda, Carlos Alberto ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Angiotensin II; Hypertension; L NAME; Losartan; Renin angiotensin system; Stereology

Indexed keywords

EID: 33846353918     PISSN: 07179367     EISSN: 07179502     Source Type: Journal    
DOI: 10.4067/S0717-95022006000400003     Document Type: Article

References (48)

1. Aguila, M. B.; Sa Silva, S. P.; Pinheiro, A. R.& Mandarim-de-Lacerda C.A. Effects of long-term intake of edible oils on hypertension and myocardial and aortic remodelling in spontaneously hypertensive rats. J. Hypertens., 22:921-9, 2004.
2. Artigues-Varin, C.; Richard, V.; Renet, S.; Henry, J.P.& Thuillez C. Lack of impairment of nitric oxide-mediated responses in a rat model of high-renin hypertension. Clin. Exp. Pharmacol. Physiol., 29:26-31, 2002.
3. Baylis, C.; Mitruka, B. & Deng, A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest., 90:278-81, 1992.
4. Campbell, D. J.; Krum, H. & Esler, M. D. Losartan increases bradykinin levels in hypertensive humans. Circulation, 111:315-20, 2005.
5. Carey R. M.; Jin, X. H. & Siragy, H. M. Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am. J. Hypertens., 14:98S-102S, 2001.
6. Carey, R. M.; Wang, Z. Q.& Siragy, H. M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension, 35:155-63, 2000.
7. Carson, F. L.; Martin, J. H.& Lynn, J.A. Formalin fixation for electron microscopy: a re-evaluation. Am. J. Clin. Pathol., 59:365-73, 1973.
8. Fukada, S. Y.; Tirapelli, C. R.; de Godoy, M. A.& de Oliveira A.M. Mechanisms underlying the endothelium-independent relaxation induced by angiotensin II in rat aorta. J. Cardiovasc. Pharmacol., 45:136-43, 2005.
9. Furchgott, R. F.& Zawadzki, J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288:373-6, 1980.
10. Gasparo, M.; Catt, K. J.; Inagami, T.; Wright J. W. & Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev., 52:415-72, 2000.
11. Glantz S. A. Primer of biostatistics, 5th ed. New York, McGraw-Hill, Medical Publishing Division, 2002.
12. Gundersen, H. J. G. Notes on the estimation of the numerical density of arbitrary profiles: the edge effect. J. Microsc., 111:219-27, 1977.
13. Gundersen, H. J. G.; Bagger, P.; Bendtsen, T. F.; Evans, S.M.; Korbo, L.; Marcussen, N.; Moller, A.; Nielsen, K.; Nyengaard, J. R.; Pakkenberg, B.; Sorensen, F. B.; Vesterby, A. & West, M. J. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS, 96:857-81, 1988.
14. Gundersen, H. J. G. & Osterby, R. Optimizing sampling efficiency of stereological studies in biology: or 'do more less well!' J. Microsc., 121:65-73, 1981.
15. Higashi, Y.; Chayama, K. & Yoshizumi, M. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr. Med. Chem. Cardiovasc. Hematol. Agents., 3:133-48, 2005.
16. Ignarro, L. J.; Buga, G. M.; Wood, K. S.; Byrns, R. E.& Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U S A., 84:9265-9, 1987.
17. Kramer, C.; Sunkomat, J.; Witte, J.; Luchtefeld, M.;Walden, M.; Schmidt, B.; Tsikas, D.; Boger, R. H.; Forssmann, W. G.; Drexler, H.& Schieffer, B. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ. Res., 90:770-6, 2002.
18. Mahmud, A. & Feely, J. Arterial stiffness and the renin-angiotensinaldosterone system. J. Renin. Angiotensin. Aldosterone Syst., 5:102-8, 2004.
19. Mandarim-de-Lacerda C. A. Stereological tools in biomedical research. An. Acad. Bras. Cienc., 75:469-86, 2003.
20. Mandarim-de-Lacerda C. A.& Pereira L. M. M. Numerical density of cardiomyocytes in chronic nitric oxide synthesis inhibition. Pathobiology, 68:36-42, 2000.
21. Mattfeldt, T.; Mall, G.; Gharehbaghi, H. & Moller, P. Estimation of surface area and length with the orientator. J Microsc., 159 ( Pt 3):301-17, 1990.
22. Mayet, J. & Hughes, A. Cardiac and vascular patho-physiology in hypertension. Heart, 89:1104-9, 2003.
23. Millatt, L. J.; Abdel-Rahman, E. M.& Siragy, H. M. Angiotensin II and nitric oxide: a question of balance. Regul. Pept., 81:1-10, 1999.
24. Moreno, H. Jr.; Metze, K.; Bento, A. C.; Antunes, E.; Zatz, R. & de Nucci, G. Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic. Res. Cardiol., 91:248-55, 1996.
25. Mulvany, M. J. Structure and function of small arteries in hypertension. J. Hypertens. Suppl., 8:S225-32, 1990.
26. Mulvany M.J. Structural abnormalities of the resistance vasculature in hypertension. J. Vasc. Res., 40:558-60, 2003.
27. Pechanova, O.; Bernatova, I.; Pelouch, V. & Babal, P. L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol. Res., 48:353-62, 1999.
28. Pechanova, O.; Dobesova, Z.; Cejka, J.; Kunes, J. & Zicha, J. Vasoactive systems in L-NAME hypertension: the role of inducible nitric oxide synthase. J. Hypertens., 22:167-73, 2004.
29. Pereira, L. M.; Bezerra, D. G.& Mandarim-de-Lacerda C.A. Aortic wall remodeling in rats with nitric oxide deficiency treated by enalapril or verapamil. Pathol. Res. Pract., 200:211-7, 2004.
30. Pereira, L. M. M.& Mandarim-de-Lacerda, C. A. Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade. Pathol. Res. Pract., 196:305-11, 2000.
31. Pereira, L. M. M.; Vianna, G. M. M.& Mandarim-de-Lacerda C.A. Stereology of the myocardium in hypertensive rats. Differences in relation to the time of inhibition of nitric oxide synthesis. Virchows Archiv., 433:369-73, 1998.
32. Pessanha, M. G. & Mandarim-de-Lacerda C. A. Myofibroblast accumulation in healing rat myocardium due to long-term low-dosage nitric oxide synthesis inhibition. Exp. Toxicol. Pathol., 52:192-4, 2000.
33. Pessanha, M. G.; Mandarim-de-Lacerda, C. A.& Hahn, M.D. Stereology and immunohistochemistry of the myocardium in experimental hypertension: Long-term and low-dosage administration of inhibitor of the nitric oxide synthesis. Pathobiology, 67:26-33, 1999.
34. Rees, D. D.; Palmer, R. M. & Moncada, S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. U S A., 86:3375-8, 1989.
35. Ribeiro, M. O.; Antunes, E.; Nucci, G.: Lovisolo, S. M. & Zatz, R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension, 20:298-303, 1992.
36. Ritter, O. & Neyses, L. The molecular basis of myocardial hypertrophy and heart failure. Trends. Mol. Med., 9:313-21, 2003.
37. Sadoshima, J. Novel AT(1) receptor-independent functions of losartan. Circ. Res., 90:754-6, 2002.
38. Scherle, W. A simple method for volumetry of organs in quantitative stereology. Mikroskopie, 26:57-60, 1970.
39. Schiffrin, E. L. Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy? Curr. Opin. Nephrol. Hypertens., 10:617-24, 2001.
40. Siragy, H. M. & Carey, R. M. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J. Clin. Invest., 97:1978-82, 1996.
41. Siragy, H. M. & Carey, R. M. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J. Clin. Invest., 100:264-9, 1997.
42. Sterio, D.C. The unbiased estimation of number and sizes of arbitrary particles using the disector. J. Microsc., 134(Pt 2):127-36, 1984.
43. Timmermans P.B. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens. Res., 22:147-53, 1999a.
44. Timmermans, P. B. Pharmacological properties of angiotensin II receptor antagonists. Can. J. Cardiol., 15 Suppl F:26F-28F, 1999b.
45. Weber, K. T. & Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation, 83:1849-65, 1991.
46. Weibel E. Stereological Methods. Practical methods for biological morphometry. London, Academic Press, 1979.
47. Widdop, R. E.; Jones, E. S.; Hannan, R. E.& Gaspari, T. A. Angiotensin AT2 receptors: cardiovascular hope or hype? Br. J. Pharmacol., 140:809-24, 2003.
48. Zhou, M.S.; Schulman, I. H.& Raij L. Nitric oxide, angiotensin II, and hypertension. Semin. Nephrol., 24:366-78, 2004.